First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Phase 1 Active not recruiting 70 enrolled TORL Biotherapeutics, LLC Translational Research in Oncology · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-MAB in patients with advanced cancer

Timeline

Start: 2022-01-20
Primary completion: 2024-12-15
Completion: 2025-12-15

Publications

O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, Madrid AM, Donahue TR, Glaspy JA, Presta L, Slamon DJ. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. Mol Cancer Ther. 2023 Dec 1;22(12):1365-1375. doi: 10.1158/1535-7163.MCT-23-0353.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TORL-2-307-MAB	Unknown	—	—

First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Summary

Timeline

Publications

Drugs

Indications